Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Stage II
Interventions: DRUG: Ribociclib (neoadjuvant)|DRUG: Chemotherapy (adjuvant)|DRUG: Ribociclib (adjuvant)
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Novartis|UNICANCER